|New Threads Only:|
|New Threads & Replies:|
Forum List » Guru News and Commentaries|
Guru News, Stock picks and commentaries
Wedgewood Partners' David Rolfe Comments on Gilead Sciences
Posted by: guruhl (IP Logged)
Date: November 12, 2012 02:01PM
Gilead Sciences (GILD) was among our top performers during the third quarter. We believe that the stock's strong performance over the past three months, as well as the past year is quite warranted, as the company is on the cutting edge in developing a cure for the hepatitis C virus (HCV). The Company’s journey down this path began last November with their $11 billion purchase of Pharmasset, Inc. Pharmasset’s flagship drug candidate (PSI-7977, now GS-7977) is undergoing trials indicated for all-oral treatment of HCV and if ultimately approved by the FDA, Gilead could possess a multi-year, multi-billion dollar revenue opportunity. We believe that the market, more recently, has better recognized this opportunity, so we trimmed our positions during the quarter.
From Wedgewood Partners Third Quarter 2012 Review and Outlook.
Guru Discussed: David Rolfe: Current Portfolio, Stock Picks
Stocks Discussed: GILD,